Sanofi (NASDAQ:SNY) Given Consensus Rating of “Hold” by Analysts

Sanofi (NASDAQ:SNY) has been given an average recommendation of “Hold” by the fifteen ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, three have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $51.00.

Several research analysts have recently weighed in on the stock. Bank of America downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday, February 12th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a research report on Friday, January 16th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. UBS Group reissued a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Finally, Wall Street Zen downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SNY. Flagship Harbor Advisors LLC purchased a new position in Sanofi during the fourth quarter valued at approximately $25,000. Financial Consulate Inc. purchased a new position in Sanofi during the third quarter valued at approximately $26,000. Physician Wealth Advisors Inc. grew its position in Sanofi by 180.5% during the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after purchasing an additional 379 shares in the last quarter. Leonteq Securities AG grew its position in Sanofi by 95.8% during the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock valued at $29,000 after purchasing an additional 297 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC purchased a new position in Sanofi during the third quarter valued at approximately $29,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

Sanofi stock opened at $46.08 on Friday. The firm’s 50 day simple moving average is $46.39 and its 200-day simple moving average is $47.91. The company has a market cap of $112.39 billion, a P/E ratio of 12.87, a price-to-earnings-growth ratio of 1.15 and a beta of 0.35. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22. Sanofi has a fifty-two week low of $43.32 and a fifty-two week high of $55.73.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Wednesday, June 3rd. Investors of record on Monday, May 4th will be given a dividend of $2.4225 per share. The ex-dividend date of this dividend is Monday, May 4th. This is a boost from Sanofi’s previous annual dividend of $2.04. This represents a yield of 502.0%. Sanofi’s payout ratio is presently 44.69%.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.